Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$494.46 USD
-11.32 (-2.24%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $494.52 +0.06 (0.01%) 7:58 PM ET
4-Sell of 5 4
D Value B Growth F Momentum D VGM
Brokerage Reports
0 items in cart
Vertex Pharmaceuticals Incorporated [VRTX]
Reports for Purchase
Showing records 281 - 300 ( 331 total )
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Technical Analysis - Biotech Stocks Ignored and Oversold, Offering Good Entry
Provider: Drexel Hamilton, LLC
Analyst: SINE B
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of April 29
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
We are dropping coverage of due to realignment of research coverage since analyst departure
Provider: WEDBUSH SECURITIES INC.
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
HCV Update: Vertex Reports Impressive Phase 1 Nuc Data; Seeking DAA(s) for Combination in Phase 2; Read-through for ACHN and IDIX
Provider: WEDBUSH SECURITIES INC.
Analyst: FELT A
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Better than Expected Results with VX-770
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: BERNARDINO V
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Upgrading to Relative OUTPERFORM and Raising PT to $51
Provider: WEDBUSH SECURITIES INC.
Analyst: XU Y
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Biotechnology / Biopharmaceuticals - Potential Q1:11 Movers
Provider: WEDBUSH SECURITIES INC.
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Potential Q1:11 Movers
Provider: WEDBUSH SECURITIES INC.
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Anticipating Telaprevir Launch in May - Raising Target Price from $45 to $48
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: BERNARDINO V
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Raising PT to $42 on Increasing Pricing of CF Franchise; Q4:10 Earnings Uneventful; Multiple Milestones in H1:11
Provider: WEDBUSH SECURITIES INC.
Analyst: XU Y
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of January 23
Provider: WEDBUSH SECURITIES INC.
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Interim ASPIRE Data of TMC435 Encouraging
Provider: WEDBUSH SECURITIES INC.
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Plans to Evaluate Three-Drug All-Oral Regimen
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: BERNARDINO V